Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

Piette, Caroline; Suciu, S; Clappier, E; Bertrand, Y; Drunat, S; Girard, S; Yacouben, K; Plat, G; Dastugue, N; Mazingue, F; Grardel, N; Van  Roy, N; Uyttebroeck, A; Costa, V; Minckes, O; Sirvent, N; Simon, P; Lutz, P; Ferster, A; Pluchart, C; Poirée, M; Freycon, C; Dresse, Marie-Françoise; Millot, F; Chantrain, C; van der Werff Ten Bosch, J; Norga, K; Gilotay, C; Rohrlich, PS; Benoit, Y; Cavé, H

doi:10.1038/leu.2017.289

Article (Scientific journals)

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

Piette, Caroline; Suciu, S; Clappier, E et al.

2018 • In Leukemia, 32, p. 244-248

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/217507

DOI
10.1038/leu.2017.289

PubMed
29064485

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Manuscript_Leukemia_2017_ETV6-RUNX1.pdf

Publisher postprint (370.36 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] In childhood B-cell precursor acute lymphoblastic leukaemias (BCP-ALL), the presence of an ETV6-RUNX1 fusion transcript defines one of the most prevalent genetic subgroups, together with the high hyperdiploidy (HeH) ALL. Although ETV6-RUNX1pos ALLs are associated with favourable outcome, their proper treatment strategies remain debatable, some groups suggesting crucial impact of upfront intensive treatment while others favour low-intensity antimetabolite-based therapy.

Disciplines :

Pediatrics
Hematology

Author, co-author :

Piette, Caroline ; Centre Hospitalier Régionale de la Citadelle (Liège) - CHR CITADELLE > Service Universitaire de Pédiatrie ULiège > Hémato-Oncologie Pédiatrique

Suciu, S

Clappier, E

Bertrand, Y

Drunat, S

Girard, S

Yacouben, K

Plat, G

Dastugue, N

Mazingue, F

More authors (21 more)

Language :

English

Title :

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

Publication date :

2018

Journal title :

Leukemia

ISSN :

0887-6924

eISSN :

1476-5551

Publisher :

Nature Publishing Group, London, United Kingdom

Volume :

Pages :

244-248

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 29 December 2017

Statistics

Number of views

233 (12 by ULiège)

Number of downloads

299 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Avigad S, Kuperstein G, Zilberstein J, Liberzon E, Stark B, Gelernter I et al. TELAML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia. Leukemia 1999; 13: 481-483.
Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 1997; 89: 1143-1146.
Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia 2000; 14: 2257-2266.
De Moerloose B, Suciu S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): Report of the EORTC randomized phase 3 trial 58951. Blood 2010; 116: 36-44.
Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 2014; 99: 1220-1227.
Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized EuropeanOrganisation for Research and Treatment of Cancer,Children's Leukemia Group phase 3 trial. Blood 2002; 99: 2734-2739.
Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G et al. Prolonged E. Coli asparaginase therapy does not improve significantly the outcome for children with low and average risk acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL): Final Report of the EORTC-CLG Randomized Phase III Trial 58951. Blood 2012; 120: abstract 134.
Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006; 107: 4508-4513.
Rubnitz JE, Wichlan D, Devidas M, Shuster J, Linda SB, Kurtzberg J et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 2008; 26: 2186-2191.
Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE et al. ETV6-RUNX1- positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2012; 26: 265-70.
Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL : results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016; 127: 2101-2113.
van der Werff Ten Bosch J, Suciu S, Thyss A, Bertrand Y, Norton L, Mazingue F et al. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG. Leukemia 2005; 19: 721-726.
Schmiegelow K, Al-modhwahi I, Andersen MK, Behrendtz M, Hasle H, Heyman M et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHOALL-92 study. Blood 2012; 113: 6077-6084.
Zaza G, Yang W, Kager L, Cheok M, Downing J, Pui CH et al. Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood 2004; 104: 1435-1441.
Masson E, Synold TW, Relling MV, Schuetz JD, Sandlund JT, Pui C-H et al. Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Leukemia 1996; 10: 56-60.